# Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease

> **NCT07753200** · PHASE4 · RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 3000 (estimated)

## Conditions studied

- Atrial Fibrillation (AF)
- Coronary Arterial Disease (CAD)

## Interventions

- **DRUG:** Edoxaban
- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT07753200
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2031-06-01
- **Final completion:** 2031-12-31
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07753200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07753200, "Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07753200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*